Advertisement
AXON vs MCRB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and MCRB is a Hold.
AXON in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Indicator exited the oversold zone, 20 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 62 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.457) is normal, around the industry mean (5.060). AXON has a moderately high P/E Ratio (173.186) as compared to the industry average of (17.792). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
MCRB's Indicator enters downward trend
The Aroon Indicator for MCRB entered a downward trend on October 30, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator formed such a pattern. In 239 of the 265 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on October 29, 2026. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
MCRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.515) is normal, around the industry mean (3.162). P/E Ratio (-0.731) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (21.008) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. MCRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | MCRB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 67 | 100 | |
SMR RATING 1..100 | 81 | 98 | |
PRICE GROWTH RATING 1..100 | 61 | 96 | |
P/E GROWTH RATING 1..100 | 51 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCRB's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for AXON (92). This means that MCRB’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for MCRB (100). This means that AXON’s stock grew somewhat faster than MCRB’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as MCRB (98). This means that AXON’s stock grew similarly to MCRB’s over the last 12 months.
AXON's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for MCRB (96). This means that AXON’s stock grew somewhat faster than MCRB’s over the last 12 months.
AXON's P/E Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for MCRB (97). This means that AXON’s stock grew somewhat faster than MCRB’s over the last 12 months.
| AXON | MCRB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | N/A |
| Stochastic ODDS (%) | 2 days ago 74% | N/A |
| Momentum ODDS (%) | 2 days ago 82% | N/A |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 90% |
| Advances ODDS (%) | 5 days ago 74% | N/A |
| Declines ODDS (%) | 13 days ago 70% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while MCRB’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- MCRB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while MCRB’s TA Score has 2 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 4 bearish.
- MCRB’s TA Score: 2 bullish, 2 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +1.76% price change this week, while MCRB (@Biotechnology) price change was -15.31% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.04%. For the same industry, the average monthly price growth was -10.06%, and the average quarterly price growth was -17.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
AXON is expected to report earnings on Nov 05, 2026.
MCRB is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Aerospace & Defense (+2.04% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement